Close menu




December 27th, 2021 | 10:45 CET

Mutares, Hong Lai Huat, Aurelius - Yield generators in 2022!

  • Investments
Photo credits: pixabay.com

Given high inflation, investing in tangible assets such as shares, real estate, and commodities is still a good idea in 2022. Substantial stocks from the investment or real estate sector that create added value for shareholders and pay attractive dividends are now worth a closer look. We checked three different companies.

time to read: 2 minutes | Author: Carsten Mainitz
ISIN: MUTARES KGAA NA O.N. | DE000A2NB650 , HONG LAI HUAT GROUP LIMITED | SG1EE1000009 , AURELIUS EQ.OPP. O.N. | DE000A0JK2A8

Table of contents:


    Mutares - All signs point to growth!

    The private equity investor acquires small to medium-sized companies and parts of groups in situations of transition, based in Europe, which have clear operational improvement potential. Mutares actively supports and develops the portfolio companies with its investment and expert teams as well as through strategic add-on acquisitions. After stabilization and repositioning, the companies are sold with a target return of 7 to 10 times the invested capital.

    In 2021, the Munich-based Company acquired 13 companies. Most recently, the footprint in Scandinavia was significantly increased in Goods & Services. In the current fiscal year, sales are expected to increase to at least EUR 2.4 billion. The Company reported in its Q3 figures that the transaction pipeline is very well filled with a sales volume of EUR 9 billion. As guidance for 2023, Mutares has set its sights on consolidated revenues of at least EUR 5 billion. With the portfolio growth, consulting revenues are also increasing, which together with portfolio dividends and exit proceeds are accruing to the Company.

    Shareholders will participate in the Company's success based on a transparent and attractive dividend policy. The medium- to long-term plan is to pay out 1.8% to 2.2% of Group sales. The sustainable dividend policy is to consist of a basic dividend and an exit-dependent performance dividend. If the medium-term targets are only half achieved, investors will be buying a stock today that should generate an annual dividend yield of well over 10% in a few years. Analysts believe the shares have an upside potential of more than 40%.

    Hong Lai Huat - Still undiscovered small-cap

    Hong Lai Huat Group Limited has been operating as a real estate developer and property developer in Singapore, which is also the Company's headquarters, since 1998. The island nation is one of Asia's most important financial centers and a central shipping hub. Singapore has first-class marks in quality of life, security and economic performance. The home ownership rate is a good 90%.

    In recent decades, the Group has completed numerous projects in the city-state, ranging from public and private residential developments to commercial and industrial buildings. Implemented projects in Singapore include D'Ecosia, D'Fresco, D'Castilia, D'Almira, D'Lithium, D'Kranji Farm Resort and D'Centennial.

    In 2008, the Group diversified into the agricultural sector in Cambodia and has since completed the development of approximately 10,000 hectares of farmland growing fresh cassava. The Group has also expanded its real estate development in Cambodia with the successful launch of its first mixed-use condominium project, D'Seaview. D'Seaview comprises 737 residential units and 67 commercial units. Recently, the Singaporeans announced the complete project sale. With a market value of SGD 50 million, investors should put the still unknown stock on their watchlist.

    Aurelius - 30% discount to NAV

    Like Mutares, Aurelius can also look back on a record year, as is evidenced by the Q3 figures. In the first nine months of the current financial year, the operating result (EBITDA) increased by 81% to EUR 181.4 million and is thus above the 2020 total profit. The basis for the increase was the dynamic development of the portfolio companies. The intrinsic value per share (net asset value) increased by 20% compared to the end of 2020 to EUR 40.43. The shares are thus trading at a discount of around 30% compared to this key figure. Aurelius took advantage of the valuation level and announced the acquisition of 1 million own shares.


    Investment companies and real estate companies offer interesting investment opportunities. Mutares and Aurelius should continue to generate respectable returns for shareholders in the future. Hong Lai Huat, which is still widely unknown, belongs on the watch list for next year.


    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.

    Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.

    The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.


    Der Autor

    Carsten Mainitz

    The native Rhineland-Palatinate has been a passionate market participant for more than 25 years. After studying business administration in Mannheim, he worked as a journalist, in equity sales and many years in equity research.

    About the author



    Related comments:

    Commented by Juliane Zielonka on September 29th, 2023 | 07:00 CEST

    Defence Therapeutics, Schott Pharma, Allianz Group: Focus on Innovation, Growth and Portfolio Optimization

    • Biotechnology
    • Pharma
    • Investments

    According to a recent study, biotech company Defence Therapeutics achieves twice the immune response of conventional mRNA therapies with its Accum® mRNA technology. That translates to fewer side effects and a more effective treatment. According to Precedence Research, the market size for mRNA therapeutics is projected to reach approximately USD 137.59 billion by 2032. It is expected to grow at a CAGR of 13.2% from 2023 to 2032. In order to inject these active ingredients, precision-fit medical vials are required, and Schott Pharma is ensuring this with their IPO launched on the German stock exchange this week, which could bring a valuation of around EUR 4 billion. The Allianz Group, on the other hand, is focusing on consolidation, selling its business in the Middle East and thus flushing around EUR 210 million cash into its coffers.

    Read

    Commented by André Will-Laudien on September 26th, 2023 | 07:45 CEST

    Artificial Intelligence in Sellout! Nvidia, Defense Metals, ARM Holdings - Nothing works without rare earths!

    • Mining
    • RareEarths
    • AI
    • chips
    • Investments

    After long bull market movements, the stock market usually tends to rotate sectors, or the market enters a general consolidation. In the former case, investors can profit by reallocating their assets while exploring new investment opportunities. In the latter case, all stocks come down, and the capital market generally suffers from a change in sentiment and corrects recently exaggerated valuations. In the case of the new megatrend of Artificial Intelligence (AI), the stock market seems to sense a great need for correction. As if by magic, the blockbuster stock Nvidia rose by 250% in just 9 months. However, it has already retraced nearly 20% from its peak. Where do the opportunities lie for investors?

    Read

    Commented by André Will-Laudien on September 22nd, 2023 | 07:20 CEST

    Recalculation! These are the bare figures: TUI, Saturn Oil + Gas, Deutsche Bank - Buy prices non-stop!

    • Mining
    • Oil
    • travel
    • Investments
    • Banking

    Companies do not always have good figures in their baggage. Analysts listen very carefully to the words of those in charge. Often, it is only a minor sentence that changes entire valuations. TUI is slowly approaching pre-COVID figures. Saturn Oil & Gas must backtrack slightly because of substantial forest fires in Alberta, and Deutsche Bank aims to finalize the Postbank project in 2023. All three stocks offer good buying opportunities because the long-term prospects are quite convincing.

    Read